Evidence map›Paper›PMID 36179754›Full record

Observational studyThe lancet. HIV2022

Differences in healthy longevity by HIV status and viral load among older South African adults: an observational cohort modelling study.

Collin F Payne, Brian Houle, Chido Chinogurei, Carlos Riumallo Herl, Chodziwadziwa Whiteson Kabudula, Lindsay C Kobayashi, Joshua A Salomon, Jennifer Manne-Goehler

Open access · bronzeAbstract readCase ReportsObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The lancet. HIV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Between living and aging: perceptions of women with HIV.Revista brasileira de enfermagem · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 4 countries.

Collin F PayneSchool of Demography, Research School of Social Sciences, The Australian National University, Canberra, ACT, Australia; Center for Population and Development Studies, Harvard T H Chan School of Public Health, Cambridge, MA, USA. Electronic address: collin.payne@anu.edu.au.
Brian HouleSchool of Demography, Research School of Social Sciences, The Australian National University, Canberra, ACT, Australia; MRC/Wits Rural Public Health and Heath Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Chido ChinogureiCentre for Infectious Diseases and Epidemiology Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Carlos Riumallo HerlSchool of Economics, Erasmus University, Rotterdam, Netherlands.
Chodziwadziwa Whiteson KabudulaMRC/Wits Rural Public Health and Heath Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Lindsay C KobayashiCenter for Social Epidemiology and Population Health, Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Joshua A SalomonCenter for Primary Care and Outcomes Research, Stanford University, Palo Alto, CA, USA.
Jennifer Manne-GoehlerDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Center for Population and Development Studies, Harvard T H Chan School of Public Health, Cambridge, MA, USA.
University of the Witwatersrand · ZAAustralian National University · AUBrigham and Women's Hospital · USErasmus University Rotterdam · NLStanford University · USUniversity of Cape Town · ZAUniversity of Michigan–Ann Arbor · US

Funding

SOCIAL AND ECONOMIC PREDICTORS OF PHYSICAL AND COGNITIVE FUNCTIONP01AG041710 · NIA · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI LISA F BERKMAN, THOMAS A GAZIANO · 2013 to 2026
$37.3M
Medical Research CouncilNIA NIH HHS P01 AG041710Wellcome TrustWellcome Trust 058893/Z/99/AWellcome Trust 069683/Z/02/ZWellcome Trust 085477/B/08/ZWellcome Trust 085477/Z/08/Z
6 · The paper itself

Abstract

backgroundThe population of people living with HIV in South Africa is rapidly ageing due to increased survivorship attributable to antiretroviral therapy (ART). We sought to understand how the combined effects of HIV and ART have led to differences in healthy longevity by HIV status and viral suppression in this context.

methodsIn this observational cohort modelling study we use longitudinal data from the 2015 baseline interview (from Nov 13, 2014, to Nov 30, 2015) and the 2018 longitudinal follow-up interview (from Oct 12, 2018, to Nov 7, 2019) of the population-based study Health and Ageing in Africa: a Longitudinal Study of an INDEPTH Community in South Africa (HAALSI) to estimate life expectancy and disability-free life expectancy (DFLE) of adults aged 40 years and older in rural South Africa. Respondents who consented to HIV testing, responded to survey questions on disability, and who were either interviewed in both surveys or who died between survey waves were included in the analysis. We estimate life expectancy and DFLE by HIV status and viral suppression (defined as <200 copies per mL) using Markov-based microsimulation.

findingsAmong the 4322 eligible participants from the HAALSI study, we find a clear gradient in remaining life expectancy and DFLE based on HIV serostatus and viral suppression. At age 45 years, the life expectancy of a woman without HIV was 33·2 years (95% CI 32·0-35·0), compared with 31·6 years (29·2-34·1) a woman with virally suppressed HIV, and 26·4 years (23·1-29·1) for a woman with unsuppressed HIV; life expectancy for a 45 year old man without HIV was 27·2 years (25·8-29·1), compared with 24·1 years (20·9-27·2) for a man with virally suppressed HIV, and 17·4 years (15·0-20·3) for a man with unsuppressed HIV. Men and women with viral suppression could expect to live nearly as many years of DFLE as HIV-uninfected individuals at ages 45 years and 65 years.

interpretationThese results highlight the tremendous benefits of ART for population health in high-HIV-prevalence contexts and reinforce the need for continued work in making ART treatment accessible to ageing populations.

fundingNational Institutes of Health.

Indexed as

HIV InfectionsAdultFemaleHIV TestingHumansLongevityLongitudinal StudiesMaleMiddle AgedSouth AfricaViral Load

Identifiers

PMID36179754
PMCPMC9553125
OpenAlexW4297231250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.